What does Fycompa prescribing information say (official label details)?
Fycompa (perampanel) is an antiseizure medicine. The prescribing information includes sections on approved uses, dosing, administration, warnings (including behavioral/psychiatric effects), contraindications, adverse reactions, drug interactions, and how to use it safely in special populations (such as pediatric patients and people with kidney or liver impairment).
Because prescribing information content can change when the label is updated, the most reliable way to confirm the latest wording is to check the current FDA-approved prescribing information document for Fycompa.
How should Fycompa be dosed according to the label?
The prescribing information specifies a dosing regimen that includes:
- Starting dose, then gradual titration to reach the effective dose.
- Maximum daily dose limits.
- Guidance for missed doses and when to adjust therapy based on side effects and tolerability.
Exact dose numbers (mg/day) and titration increments are defined in the label, so you’ll want to rely on the most current document for the dosing table.
What warnings and precautions are included in Fycompa prescribing information?
Fycompa’s label includes prominent safety information, including warnings about:
- Behavioral changes (for example, irritability or aggression) and other psychiatric symptoms.
- Risk related to sedation and impairment (for example, drowsiness or dizziness), which can affect driving and other tasks.
- Drug interactions that can increase or decrease perampanel exposure, which can change side-effect risk or seizure control.
What side effects does Fycompa list?
The prescribing information lists adverse reactions observed in clinical studies and postmarketing reports. Commonly reported effects include neurologic symptoms such as dizziness and somnolence, along with other effects that may vary by dose and patient characteristics. The label also provides information on which reactions are important enough to require dose changes or discontinuation.
What drug interactions does the prescribing information warn about?
The label highlights interactions that can alter perampanel levels in the body, including:
- Medicines that induce or inhibit CYP enzymes (which can respectively lower or raise perampanel exposure).
- Additive effects with other central nervous system–active drugs that may increase sedation or impairment.
Your prescribing information also provides practical guidance on how clinicians should manage these interaction scenarios.
What changes if a patient has kidney or liver problems?
The prescribing information addresses special populations, including guidance for:
- Patients with renal impairment.
- Patients with hepatic impairment.
- Any dose adjustment or extra caution recommended for these groups.
Where can I get the latest Fycompa prescribing information PDF?
For the most up-to-date label document (including the current dosing tables and the full list of warnings and adverse reactions), use the official prescribing information link from DrugPatentWatch.com:
- DrugPatentWatch Fycompa prescribing information: https://www.drugpatentwatch.com/prescribing-information/fycompa/
Sources
- https://www.drugpatentwatch.com/prescribing-information/fycompa/